PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.

Authors

Dung Le

Dung T. Le

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Dung T. Le , Jennifer N. Uram , Hao Wang , Holly Kemberling , Aleksandra Eyring , Bjarne Bartlett , Richard M. Goldberg , Todd S. Crocenzi , George A. Fisher , James J. Lee , Tim F. Greten , Dan Laheru , Nilofer Saba Azad , Ross C. Donehower , Brandon Luber , Minori Koshiji , James R. Eshleman , Robert A Anders , Bert Vogelstein , Luis A. Diaz Jr.

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Translational Research

Clinical Trial Registration Number

NCT01876511

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr 195)

DOI

10.1200/jco.2016.34.4_suppl.195

Abstract #

195

Poster Bd #

A5

Abstract Disclosures

Similar Posters

Poster

2017 ASCO Annual Meeting

Response to pembrolizumab in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC).

Response to pembrolizumab in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC).

First Author: Alexis Diane Leal

Poster

2017 Gastrointestinal Cancers Symposium

Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience.

Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience.

First Author: Courtney C Cavalieri

First Author: Bahar Saberzadeh Ardestani